{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"20"}],"units":"Participants"}],"description":"Number (percentage) of patients experiencing at least one treatment-emergent adverse event, defined as those untoward medical events with onset after the first dose of study drug or existing events that worsened after the first dose during the study","groups":[{"description":"Patients with relapsed or refractory EBV-positive diffuse large B-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG000","title":"Diffuse Large B-Cell Lymphoma"},{"description":"Patients with relapsed or refractory EBV-positive extranodal natural killer/T-cell lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG001","title":"Extranodal Natural Killer/T-Cell Lymphoma"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG002","title":"Peripheral T-Cell Lymphoma (Combination Therapy)"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week","id":"OG003","title":"Peripheral T-Cell Lymphoma (Monotherapy)"},{"description":"Patients with relapsed or refractory EBV-positive Hodgkin lymphoma treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG004","title":"Hodgkin Lymphoma"},{"description":"Patients with relapsed or refractory EBV-positive post-transplant lymphoproliferative disorders treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG005","title":"Post-Transplant Lymphoproliferative Disorders"},{"description":"Patients with relapsed or refractory EBV-positive human immunodeficiency virus-associated lymphomas treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG006","title":"Human Immunodeficiency Virus-Associated Lymphomas"},{"description":"Patients with relapsed or refractory EBV-positive lymphomas other than those from the other cohorts treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG007","title":"Other EBV-Positive Lymphomas"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set, defined as all enrolled patients who received at least 1 dose of study treatment.\n\nThe study was not designed to make formal statistical comparisons of AE numbers (percentages) between cohorts.","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Number (Percentage) of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}